Nanoparticulate drug delivery systems for cancer chemotherapy

References

• Allenmann E, Leroux JC, Gurny R, Doelker E. 1993. In vitro extended-release properties of drug-loaded poly (DL-lactic acid) NPs produced by a salting-out procedure. Pharm Res 10:1732–1737.
   PubMedGoogle Scholar
• Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. 2006. Preparation and characterization of protein-loaded N-trimethyl Chitosan nanoparticles as nasal delivery system. J Control Rel 111:107–116.
   PubMed Web of Science ®Google Scholar
• Aston R, Siebert RS, Canham L, Ogden J. 2005. Nanotechnology application for drug delivery. Pharmaceut Technol Eur 17:21–28.
   Google Scholar
• Bilati U, Allemann E, Doelker E. 2005. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSciTech 6:E594–604.
   PubMed Web of Science ®Google Scholar
• Borgia SL, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Röder B, Kramer KD, Korting MS. 2005. Lipid nanoparticles for skin penetration enhancement – correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Rel 110:151–163.
   PubMed Web of Science ®Google Scholar
• Breunig M, Bauer S, Goepferich A. 2008. Polymer and nanoparticles: Intelligent tools for intracellular targeting? Eur J. Pharm Biopharm 68:112–128.
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 54:631–651.
   PubMed Web of Science ®Google Scholar
• Champion JA, Katare YK, Mitragotri S. 2007. Particle shape: A new design parameter for micro and nanoscale drug delivery carriers. J Control Rel 121:3–9.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Kante B, Roland M, Guiot P, Bauduin P. Speiser P. 1979. Polycyanoacrylate nanocapsules as potential lysosomatropic carriers: Preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331–332.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. 2006. Nanotechnology: Intelligent design to treat complex disease. Pharm Res 23:1417–1450.
   PubMed Web of Science ®Google Scholar
• Cummings J, Allan L, Smyth J. 1994. Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinine reduction in tumor tissue and antitumor activity. Biochem Pharmacol 47:1345–1356.
   PubMedGoogle Scholar
• Daemen T, Hofstede G, Kate MTT, Woudenberg IAJMB, Scherphof G. 1995. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 61:716–721.
   PubMed Web of Science ®Google Scholar
• Dass CR. 2002. Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumor gene therapy. Int J Pharm 241:1–25.
   PubMed Web of Science ®Google Scholar
• De Campos AM, Sanchez A, Alonso MJ. 2001. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporine A. Int J Pharm 224:159–168.
   PubMed Web of Science ®Google Scholar
• Derakhshandeh K, Erfan M, Dadashzadeh S. 2007. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur J Pharm Biopharm 66:34–41.
   PubMed Web of Science ®Google Scholar
• Desgouilles S, Vauthier C, Bazile D, Vacus J, Grossiord L, Veillard M, Couvreur P. 2003. The design of nanoparticles obtained by solvent evaporation: A comprehensive study. Langmuir 19:9504–9510.
   Web of Science ®Google Scholar
• Dillen K, Vandervoort J, Mooter GV, Ludwig A. 2006. Evaluation of ciprofloxacin-loaded Eudragit RS 100 or Rl 100/PLGA nanoparticles. Int J Pharm 314:72–82.
   PubMed Web of Science ®Google Scholar
• Discher DE, Eisenberg A. 2002. Material science: soft surface: polymer vesicles. Science 297:967–973.
   PubMed Web of Science ®Google Scholar
• Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688–701.
   PubMed Web of Science ®Google Scholar
• Fahmy TM, Fong PM, Park J, Constable T, Saltzman WM. 2007. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 9(2):E171–180.
   Google Scholar
• Florence AT, Hussain N. 2001. Trancytosis of nanoparticles and dendrimers delivery system: Evolving vistar. Adv Drug Deliv Rev 50:S69–89.
   PubMed Web of Science ®Google Scholar
• Gao X, Wu B, Zhang Q, Chen J, Zhu J, Zhang W, Rong Z, Chen H, Jiang X. 2007. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 121:156–167.
   PubMed Web of Science ®Google Scholar
• Gaur U, Sahoo SK. 2000. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 202:1–10.
   PubMed Web of Science ®Google Scholar
• Gill S, Lobenberg R, Ku T, Azarmi S, Roa W, Prenner EJ. 2007. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery – a review. J Biomed Nanotechnol 3:107–119.
   Web of Science ®Google Scholar
• Girish B, Kollipara S, Kolachina V, Saha R. 2007. Development and validation of a stability indicating RP-LC method for determination of Imatinib Mesylate. Chromatographia 66:859–866.
   Google Scholar
• Graham ML. 2003. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 55:1293–1302.
   PubMed Web of Science ®Google Scholar
• Grau MJ, Kayser O, Muller RH. 2000. Nanosuspension of poorly soluble drugs-reproducibility of small scale production. Int J Pharm 196:155–157.
   PubMed Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, Domb A, Trubetskoy V, Torchilin V, Langer R. 1997. Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603.
   Google Scholar
• Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221.
   PubMed Web of Science ®Google Scholar
• Hasani S, Pellequer Y, Lamprechi A. 2009. Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm Res 26(5):1149–1154.
   PubMedGoogle Scholar
• Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. 2000. Opening between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363–1380.
   PubMed Web of Science ®Google Scholar
• Hassan AS, Sapin A, Lamprecht A, Emond E, Ghazouani El, Maincent P. 2009. Composite microparticles with in vivo reduction of the burst release effect. Eur J Pharm Biopharm 73:337–344.
   PubMedGoogle Scholar
• Kemken J, Ziegler A, Muller BW. 1992. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsion as vehicle. Pharm Res 9:554–558.
   PubMed Web of Science ®Google Scholar
• Kim SE, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF. 2009. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res 26(5):1155–1161.
   PubMedGoogle Scholar
• Kisel MA, Perez-soler R, Cruz ME. 2001. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: Studies in the rat. Int J Pharm 216:105–114.
   PubMed Web of Science ®Google Scholar
• Klaus Z, Julia K, Ernst W, Conrad C. 2004. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharmaceut Sci 7(4):22–28.
   Google Scholar
• Kollipara S, Girish B, Snehalatha M, Saha RN. 2010. Application of rotatable central composite design in the preparation and optimization of poly (lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm (Posted online on June 14, 2010, doi: 10.3109103639045.2010.487263).
   Google Scholar
• Korting MS, Mehnert W, Korting HS. 2007. Lipid nanoparticles for improved topical application of drug for skin diseases. Adv Drug Deliv Rev 59:427–443.
   PubMed Web of Science ®Google Scholar
• Kreuter J. 2001. Nanoparticulate system for brain delivery of drug. Adv Drug Deliv Rev 47:65–81.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Schafer U, Lehr CM. 2001. Size dependent targeting of micro-and nanoparticles carriers to the inflamed colonic mucosa. Pharm Res 18:788–793.
   PubMed Web of Science ®Google Scholar
• Langer R. 1998. Drug delivery and targeting. Nature 392:5–10.
   PubMed Web of Science ®Google Scholar
• Letchford K, Burt H. 2007. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structure: Micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65:259–269.
   PubMed Web of Science ®Google Scholar
• Links M, Brown R. 1999. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Anticancer Ther 1999:1–21.
   Google Scholar
• Maeda H, Sawa T, Konno T. 2001. Mechanism of tumor-targeted delivery of macromolecular drug including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61.
   PubMed Web of Science ®Google Scholar
• Maeda H, Bharate GY, Daruwalla J. 2009. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419.
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 290:137–144.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yamamoto T, Kamata R, Marda H. 1984. Pathogenesis of serratial infection: Activation of the Hageman facto-perkallikerin cascade by serratial protease. J Biochem 96:739–749.
   PubMed Web of Science ®Google Scholar
• Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. 2007. Nanoparticles: Pharmacological and toxicological significance. Br J Pharmacol 150:552–558.
   PubMed Web of Science ®Google Scholar
• Miller NS, Johnston TP. 2005. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm 294:201–216.
   PubMed Web of Science ®Google Scholar
• Miklos GL. 2005. The human cancer genome project-one more misstep in the war on cancer. Nat Biotechnol 23:535–537.
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Takahashi A, Kubo W. 2003. Poly n-butyl cyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: In vitro release and in vivo skin penetration. J Pharm Pharmaceut Sci 6(2):240–245.
   Google Scholar
• Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283–218.
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. 2003. PLGA/TPGS nanoparticles for controlled release of paclitaxel: Effect of the emulsion and drug loading ratio. Pharm Res 20:1864–1872.
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtka M, Wilsing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatolodical preparation. Adv Drug Deliv Rev 1:S131–155.
   Google Scholar
• Nguyen CA, Kouakou YNK, Allemann E, Doelker E, Guerrero DQ, Fessi H, Gurny R. 2006. Preparation of surfactant-free nanoparticles of methacrylic acid copolymer used for film coating. AAPS PharmSciTech 7:E1–7.
   Google Scholar
• Osborne DW, Ward AJ, Neil KJ. 1991. Microemulsions as topical delivery vehicles: In-vitro transdermal studies of a model hydrophilic drug. J Pharm Pharmacol 43:450–454.
   PubMed Web of Science ®Google Scholar
• Otsuka H, Nagasaki Y, Kataoka K. 2003. PEGylated nanoparticles or biological and pharmaceutical applications. Adv Drug Deliv Rev 55:403–419.
   PubMed Web of Science ®Google Scholar
• Owens DE III, Peppas NA. 2006. Opsonization, biodistribution and pharmacokinetics of polymer nanoparticles. Int J Pharm 307:93–102.
   PubMed Web of Science ®Google Scholar
• Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. 2002. Rapid endo-lysosomal escape of poly (D, L-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 16:1217–1226.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. 2003a. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329–347.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. 2003b. Dynamics of endocytosis and exocytosis of poly (D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 20:110–118.
   PubMedGoogle Scholar
• Pople PV, Singh KK. 2006. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 7(4):E1–7.
   Google Scholar
• Saez A, Guzman M, Molpeceres J, Aberturas MR. 2000. Freeze-drying of polycaprolactone and poly (D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetic of loaded drugs. Eur J Pharm Biopharm 50:379–387.
   PubMed Web of Science ®Google Scholar
• Salamanca AE, Diebold Y, Calonge M, Vazquez CG, Callejo S, Vila A, Aloso MJ. 2006. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest. Ophthalmol Vis Sci 47(4):1416–1425.
   PubMedGoogle Scholar
• Sekar V, Selladurai ST, Saha RN. 2009. A new, simple HPLC method for estimation of paclitaxel in micro-volume rat plasma. AAPS J 11(S2):1953.
   Google Scholar
• Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M, Zara GP. 2004. Cytotoxicity of anticancer drug incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 58:673–680.
   PubMed Web of Science ®Google Scholar
• Shabbits JA, Krishna R, Mayer LD. 2001. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 1:585–594.
   PubMedGoogle Scholar
• Sinjan De, Miller DW, Robinson DH. 2005. Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells. Pharm Res 22:766–775.
   PubMedGoogle Scholar
• Skipper H, Schabel J, Wilcox W. 1964. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with ‘curability’ of experimental leukemia. Cancer Treat Rep 55:1–111.
   Google Scholar
• Snehalatha M, Venugopal K, Saha RN, Babbar AK, Sharma RK. 2008a. EP loaded PLGA and PCL nanoparticles II: Biodistribution and pharmacokinetic after radiolabeling with Tc-99m. Drug Deliv 15:277–287.
   PubMed Web of Science ®Google Scholar
• Snehalatha M, Venugopal K, Saha RN. 2008b. Etoposide-loaded PLGA and PCL nanoparticles I: Preparation and effect of formulation variables. Drug Deliv 15:267–275.
   Web of Science ®Google Scholar
• Stephanie EAG, Patrick DP, Jin L, Ji G, Moo JC, De Simone JM. 2007. Nanofabricated particles for engineered drug therapies: A preliminary biodistribution study of PRINT nanoparticles. J Control Release 121:10–18.
   PubMedGoogle Scholar
• Stewart BW, Kleihues P. 2003. World cancer report – International agency for research on cancer (IARC), Non-serial publication. Geneva: World Health Organization.
   Google Scholar
• Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, Irving MP, Purkiss SC, Tadros TF, Davis SS. 1994. Surface modification of poly (lactide-co-glycolide) nanospheres by biodegradable poly (lactide)-poly (ethylene glycol) copolymers. Pharm Res 11:1800–1808.
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. 2001. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 50:S91–101.
   PubMed Web of Science ®Google Scholar
• Torchilin V. 2007. Targeted pharmaceutical nanocarriers for cancer theraphy and imaging. AAPS J 9(2):E128–147.
   Google Scholar
• Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F. 2007. Targeting the central nervous system: In vivo experiment with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 122:1–9.
   PubMed Web of Science ®Google Scholar
• Trotta M. 1999. Influence of phase transformation on indomethacin release from microemulsion. J Control Rel 60:399–405.
   PubMed Web of Science ®Google Scholar
• Tsinontides SC, Rajniak P, Hunke WA, Placek J, Reynolds SD. 2004. Freeze drying-principle and practice for successful scale-up to manufacturing. Int J Pharm 280:1–16.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Labarre D, Ponchel G. 2007. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Targeting 15:641–663.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Bouchemal K. 2008. Method for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26:1025–1058.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Cabane B, Labarre D. 2008. How to concentrate nanoparticles and avoid aggregation? Eur J Pharm Biopharm 69:466–475.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Khar RK. 2001. Targeted and controlled drug delivery. New Delhi, India: CBS Publisher and Distributor.
   Google Scholar
• Wilson B, Samanta MK, Santhi K, Sampath KKP, Paramakrishnan N, Suresh B. 2008. Targeted delivery of tacrine into the brain with polysorbates 80-coated poly (n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 70:75–84.
   PubMed Web of Science ®Google Scholar
• Xiong R, Lu W, Yue P, Xu R, Li J, Chen T, Wang P. 2008. Distribution of an i.v. injectable nimodipine nanosuspension in mice. J Pharm Pharmacol 60:1155–1159.
   PubMedGoogle Scholar
• Yang W, Peters JI, Williams RO III. 2008. Inhaled nanoparticles – a current review. Int J Pharm 356:239–247.
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumuar D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752–3756.
   PubMed Web of Science ®Google Scholar
• Zili Z, Sfar S, Fessi H. 2005. Preparation and characterization of poly-caprolactone nanoparticles containing griseofulvin. Int J Pharm 294:261–267.
   PubMed Web of Science ®Google Scholar